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Abstract  
Aim 
The oral mucosa possesses a non-neuronal cholinergic system. This study aimed to 
determine clinical evidence for a role of cholinergic mechanisms in the pathogenesis 
of periodontal diseases.  
Materials and Methods 
Fifty healthy participants, 52 patients with gingivitis and 49 with periodontitis were 
recruited. Full periodontal parameters were recorded and saliva and gingival 
crevicular fluid (GCF) collected. Levels of acetylcholine and inflammatory mediators 
were quantified using commercially available assay kits. Acetylcholinesterase and 
butyrylcholinesterase activity were measured using a published biochemical assay.  
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Results 
Acetylcholine levels are significantly elevated in saliva and GCF, whereas GCF 
levels of butyrylcholinesterase activity are significantly decreased, in patients with 
periodontal diseases.  Acetylcholine levels in saliva and GCF correlated positively 
with clinical markers of disease severity and with increased levels of IL-17A and IL-
17F. In contrast, butyrylcholinesterase activity levels in GCF showed significant 
negative correlations with clinical markers of disease severity and IL-17A and IL-17F 
levels. None of the findings were due to smoking. 
Conclusions 
Elevated acetylcholine levels and reduced butyrylcholinesterase activity are clinically 
associated with periodontal diseases and elevated levels of IL-17A and IL-17F. 
Therefore, non-neuronal cholinergic mechanisms may influence IL-17 biology and 
the aetiopathogenesis of periodontal diseases and therefore are possible therapeutic 
targets. 
Clinical Relevance 
Scientific rationale for study: The oral mucosa possesses non-neuronal cholinergic 
mechanisms. Mucosal cholinergic mechanisms are associated with inflammatory diseases 
and important for maintenance of barrier function and modulating immune responses. The 
role of cholinergic mechanisms in the aetiopathogenesis of periodontal diseases is unknown.  
 
Principal findings: Perturbations in salivary and gingival crevicular fluid levels of 
acetylcholine and butyrylcholinesterase activity are associated with severity of periodontal 
diseases and levels of IL-17A and IL-17F.  
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Practical implications: The data demonstrates the need for further study into the role of 
cholinergic mechanisms in periodontal diseases and provide evidence that cholinergic 
mechanisms may be therapeutic targets.  
 
Introduction 
The role of non-neuronal acetylcholine (ACh) as a cytotransmitter is well established 
(Wessler and Kirkpatrick, 2008). Choline acetyltransferase (ChAT) is responsible for the 
synthesis of ACh from acetyl coenzyme A and choline. ACh signalling is mediated by 
muscarinic and nicotinic receptors. Both receptor subtypes are found to be expressed by 
non-neuronal cells (Albuquerque et al., 2009). 
 
ACh is extremely labile due to the action of esterases (Klapproth et al., 1997). In humans 
acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are responsible for the 
hydrolysis of acetylcholine to acetic acid and free choline (Grando et al., 1993).  
 
The oral mucosa can be definedas having a non-neuronal cholinergic system (Nguyen et al., 
2000, Arredondo et al., 2003, Macpherson et al., 2014, Zoheir et al., 2012) due to the fact it 
expresses ChAT, acetylcholine receptors and cholinesterases (Wessler and Kirkpatrick, 
2008, Rana et al., 2010). Roles for non-neuronal ACh within mucosal tissues include; cell 
proliferation and differentiation, cytoskeletal organization, cell–cell contact, maintenance of 
effective barrier functions, controlling ion and water movements and modulation of immune 
responses (Wessler and Kirkpatrick, 2008, Macpherson et al., 2014).  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The role of ACh as an immunomodulatory neuroendocrine mediator first came to 
prominence with the discovery of the ‘cholinergic anti-inflammatory pathway’ (Borovikova et 
al., 2000). In this pathway, signals transmitted by parasympathetic nervous system induce 
the activation and release of ACh by a novel choline acetyltransferase positive (ChAT+) T 
cell subset which subsequently down regulates proinflammatory cytokine expression by 
localised macrophages in the spleen via the α7 nicotinic receptor (α7nAChR) (Rosas-Ballina 
et al., 2011, Martelli et al., 2016).  ChAT+ T cells can also emigrate to peripheral sites and 
mediate parasympathetic anti-inflammatory effects within mucosal tissues (Dhawan et al., 
2016). ChAT+ B cell populations in the intestinal mucosa have also been found to release 
ACh upon antigen stimulation which in turn modulates neutrophil recruitment (Reardon et al., 
2013). Furthermore, oral keratinocytes have been found to release ACh in response to 
stimulation by Porphyromonas gingivalis and the α7nAChR on oral keratinocytes has been 
demonstrated to downregulate P. gingivalis induced expression of IL-8 (CXCL8) 
(Macpherson et al., 2014). The evidence therefore, suggests that ACh can modulate innate 
immune responses within the oral mucosa and subsequently the pathogenesis of periodontal 
diseases (Zoheir et al., 2012). 
 
 In vivo models have demonstrated a role for cholinergic systems in the pathogenesis of 
inflammatory diseases (Hoover, 2017). However, there is a fundamental lack of clinical 
studies associating ACh or cholinesterase activity with disease outcomes. ACh levels have 
been associated with diseases of impaired cognitive function (Jia et al., 2004, Yamada et al., 
1996) and, with respect to the oral cavity, one study demonstrated that ACh levels in gingival 
tissue are elevated during inflammation (Rajeswari and Satyanarayana, 1990). Furthermore, 
cholinesterase activity has been measured in saliva to determine its use as a diagnostic 
marker of Alzheimer’s disease (Sayer et al., 2004). To date, however, no studies have 
investigated whether cholinergic mediators are associated with periodontal diseases. 
Therefore, the aim of this study was to determine if ACh and esterase activity could be 
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measured in saliva and GCF and determine their relationship with levels of 
immunoregulatory mediators and clinical outcomes of periodontal diseases.  
 
Materials and Methods  
Ethics 
The study was conducted in full accordance with ethical principles, including the World 
Medical Association Declaration of Helsinki, and was approved by the Ethics Committee of 
the School of Dentistry, Aristotle University of Thessaloniki (AUTh), Greece (9/28.01.2014).  
 
Study Population  
A total of 151 individuals were recruited from either patients attending the Lab of Preventive 
Dentistry, Periodontology and Implant Biology for periodontal treatment, or from faculty 
members and postgraduate students, at AUTh. Probing pocket depth (PPD); clinical 
attachment levels (CAL); bleeding on probing (BOP) and plaque indices (PI) were 
determined at six sites per tooth by a calibrated single examiner (AI). PPD and CAL were 
measured using an electronic constant-force (15g pressure) probe (FP32, software version 
9; Florida Probe Corporation©, Florida, USA) to the nearest 0.2 mm.  
 
Inclusion criteria: (i) Periodontitis patients (n=49) having at least two sites per quadrant with 
PPD and CAL >5mm and radiographic evidence of bone loss; (ii) Gingivitis patients (n=52) 
presenting with BOP at >30% of sites, PPD <4mm and no radiographic evidence of bone 
loss; and (iii) healthy subjects (n=50) having <10% sites with BOP, and no sites with PPD 
>3mm and CAL >4mm.  
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 Exclusion criteria: presence of <18 teeth (excluding third molars), periodontal treatment 
within the past 12 months, history of systemic disease, pregnancy or lactation, and 
prophylactic antibiotics, cholinergic therapies or anti-inflammatory medications within the last 
3 months.  
Saliva and GCF collection 
Unstimulated whole saliva was collected in the morning preceding all other assessments 
following an overnight fast during which subjects were requested not to drink (except water) 
or chew gum (Navazesh, 1993). The saliva was centrifuged at 4000 rpm for 20 minutes at 20 
oC to remove debris and the supernatant stored at -80 oC until required for analysis. 
 
GCF was collected using Periopaper (OraFlow Inc., Smithtown, NY, USA) over 30 s as 
previously described (Awang et al., 2014) from four sites per patient that were non-adjacent, 
had no endodontic involvement and were the deepest in each quadrant (sPPD, sCAL both 
>5 mm for periodontitis cases). The strips were pooled and the GCF eluted into 1 ml of 
phosphate buffered saline (PBS) containing 0.1% (w/v) bovine serum albumin (BSA) and 
stored at -80 oC until further analysis. 
 
Quantification of Acetylcholine levels in Saliva and gingival crevicular fluid 
Levels of ACh were quantified using the Acetylcholine Assay Kit (Abcam, Cambridge, UK) in 
colorimetric assay mode as previously described (Reale et al., 2012). Briefly, to determine 
total choline, 50 µl of saliva or GCF eluate was mixed with 50 μL of a reaction solution 
containing: choline assay buffer, choline probe, enzyme mix and acetylcholinesterase 
(AChE). Free choline was determined as above except for omitting the AChE. A standard 
curve was generated using a supplied choline standard. Each sample was analysed in 
triplicate. The reactions were allowed to proceed for 30 minutes at room temperature in the 
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dark and colorimetric changes at 570 nm read on a plate reader (BMG-Labtech, Ortenberg, 
Germany). Acetylcholine levels were determined using the following equation: Acetylcholine 
= Total choline – Free choline. 
 
Measurement of cholinesterase activity in saliva and GCF 
Analysis of AChE and BChE activity levels was performed as described by Naik et al (Naik 
et al., 2013). Briefly, 10 µl of saliva or 20 µl of GCF was added to 50 mM sodium phosphate 
buffer, pH 8.0; 1.3 mM 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) and 20 mM ethopropazine 
or 500 nM huperzine A to a final volume of 250 µl. Following incubation at 22 oC for 20 min, 
50 µl of 6 mM Acetylthiocholine (ATC) or Butyrylthiocholine (BTC) was added and rates of 
ATC/BTC hydrolysis were obtained by reading the plates at 412 nm for 10 min. The rates of 
substrate hydrolysis were corrected for a 1 cm path length, dilution factor and an extinction 
coefficient of 14.15 x 103 M/cm for DTNB to obtain activity in units per ml (Eyer et al., 2003). 
One unit (U) of enzyme activity is defined as the hydrolysis of 1 µM of substrate in 1 minute. 
 
Determination of cytokine and soluble receptor levels in saliva and GCF 
Levels of IL-4, IL-6, TNF, IL-17A, IL-17F and IL-17E (all Peprotech, UK), IL-17A/F and IL-
23R, (both R&D Systems, UK), TGF-β and IL-23 (both Mabtech, Sweden) were determined 
using commercially available ELISA kits as per the manufacturer’s instructions. The limits of 
detection were determined as two mean standard deviations higher than the mean baseline 
from six replicate standard curves: IL-4, IL-6, TNF, IL-17A and IL-17F = 1.9 pg/ml; IL-17E = 
3.8 pg/ml; IL-17A/F, IL-23R, TGF-β and IL-23 = 4.2 pg/ml. The IL-17A:IL-17E ratio was 
determined as previously described (Awang et al., 2014). 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Statistical analysis 
A statistical power calculation was performed based on the assumption that the data were 
normally distributed (or log normally distributed) and that Central Limit Theorem applied. 
After adjusting α to 0.05/3 for the comparison of 3 groups and using effect sizes of 0.7 with 
parametric statistical tests the average numbers per group required to exceed 80% statistical 
power were n=45.  
 
Statistical analysis was performed using an ANOVA and a multivariate analysis in a General 
Linear Model. Adjustments were made for potential confounding factors such as age and 
smoking using least-square regression analysis. The figures show unweighted results; 
however, the statistical differences indicated reflect the results of the weighted analyses.  
 
Associations between data were assessed using a Pearson correlation coefficient. All tests 
were performed at α=0.05 significance level. Partial correlation analysis adjusting for age 
was used to explore potential associations. The large variation in cigarette usage meant 
partial correlation analysis correcting for smoking was statistically impossible. Therefore, 
analysis was also performed separately on the never smoker subjects to ascertain which 
associations remained after removal of smoking completely as a confounding factor.  
Results 
 
Study Population  
Table 1 shows the proportion of subjects who smoked was significantly greater in the 
gingivitis group and the periodontitis group compared to the healthy group (both p<0.05). In 
addition, the cigarettes/day*yr was significantly greater in the periodontitis group compared 
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to the healthy group (p<0.05). The age of the subjects was also significantly higher in the 
periodontitis group compared to the healthy group (both p<0.001).  
 
All clinical parameters measured, after weighting for age and smoking status, were 
significantly greater in the gingivitis group and periodontitis group compared to the healthy 
group (all p<0.001). All clinical parameters measured except PI and sPI were significantly 
greater in the periodontitis group compared to the gingivitis group (all p<0.001).  
 
Acetylcholine levels and cholinesterase activity in saliva and gingival crevicular fluid 
Figure 1A shows that salivary levels of ACh were significantly elevated in the periodontitis 
group compared to the healthy group (p<0.01) and the gingivitis group (p<0.05). Figure 1B 
shows that GCF levels of ACh were significantly elevated in the periodontitis group 
compared to the healthy group (p<0.001) and the gingivitis group (p<0.001).  
 
No significant inter-group differences were observed with respect to salivary (Figure 2A) and 
GCF (Figure 2B) AChE activity and salivary BChE activity (Figure 2C). However, GCF BChE 
activity was significantly decreased in the periodontitis (p<0.01) and gingivitis group (p<0.05) 
compared to the healthy group (Figure 2D). 
 
Cytokine and soluble receptor levels in saliva and GCF 
Table 2A shows that salivary levels of IL-17A, IL-17A/F, IL-4 and the IL-17A:IL-17E ratio 
were significantly increased in the periodontitis group compared with the healthy group (all 
p<0.01). Furthermore, salivary levels of IL-17A, IL-17A/F, and the IL-17A:IL-17E ratio were 
significantly increased in the periodontitis group compared to the gingivitis group (all 
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p<0.05). 
 
Table 2B shows that GCF levels of IL-17A, IL-17F, IL-17A/F and the IL-17A:IL-17E ratio 
were all significantly increased in the gingivitis group compared to the healthy group (all 
p<0.05). GCF levels of IL-17A, IL-17F, IL-6 and the IL-17A:IL-17E ratio were all significantly 
increased in the periodontitis group compared to the healthy group (all p<0.05). In addition, 
GCF levels of TGF-β are significantly decreased in the periodontitis group compared to the 
healthy group (p<0.05). Furthermore, GCF levels of IL-17A, IL-17F and IL-6 were all 
significantly increased in the periodontitis group and IL-17A/F levels significantly decreased 
compared to the gingivitis group (all p<0.05). 
 
Correlations between acetylcholine levels and esterase activity in saliva and GCF and 
clinical parameters 
Table 3A shows the major correlations between salivary levels of ACh, esterase activity and 
clinical parameters. The key findings are as follows: Salivary levels of ACh had weak 
significant positive correlations with all clinical indices when all participants (n=151; all 
p<0.05) and never smokers (n=94; all p<0.05) were considered. Saliva AChE activity 
showed a moderate to strong significant positive correlation with BChE activity in all 
participants (p<0.001) and never smokers (p<0.001). Saliva BChE activity also showed a 
weak significant positive correlation with mean PD ≥5 mm in all participants (p<0.05).  
 
Table 3B shows the major correlations between GCF levels of ACh, esterase activity and 
clinical parameters. The key findings are as follows: GCF levels of ACh had a weak 
significant positive correlation with BChE only when all participants were considered (all 
p<0.01). GCF levels of ACh showed moderate to strong significant positive correlations with 
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sBOP, sPI, sPPD and sCAL when all participants (n=151; all p<0.001) and never smokers 
(n=94; all p<0.001) were considered. A significant weak negative correlation between BChE 
activity and sBOP, sPPD and sCAL was also determined in all participants (all p<0.01) and 
never smokers (all p<0.05). 
 
Correlations between acetylcholine levels and esterase activity in saliva and GCF and 
levels of selected inflammatory mediators 
 
Table 4A shows the major correlations between salivary levels of ACh, esterase activity and 
levels of selected inflammatory mediators. The key finding was that salivary levels of ACh 
had weak significant positive correlations with IL-17A and IL-17A/F when all participants 
were considered (both p<0.05) but not in never smokers.  
 
Table 4B shows the major correlations between GCF levels of ACh, esterase activity and 
levels of selected inflammatory mediators. The key findings are as follows: 
GCF levels of ACh had moderate to strong significant positive correlations with IL-17A and 
IL-17F in all participants (both p<0.001) and never smokers only (p<0.001). ACh levels had a 
significant weak positive correlation with the IL-17A:IL-17E ratio and levels of IL-6 only when 
all participants were considered (both p<0.01). GCF BChE activity showed significant weak 
negative correlations with levels of IL-17A and IL-17F in all participants (both p<0.01) and 
never smokers (both p<0.05). GCF BChE activity showed significant weak negative 
correlations with IL-17A/F in never smokers only (p<0.01). GCF BChE activity showed 
significant weak negative correlations with the IL-17A:IL-17E ratio and levels of IL-6 in all 
participants only (both p<0.05).  
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Discussion  
The data in this manuscript provide clinical evidence that cholinergic mechanisms may play 
a role in the pathogenesis of periodontal diseases. Significantly elevated levels of ACh are 
found in saliva and GCF of patients with gingivitis and periodontitis. Furthermore, GCF levels 
of ACh showed significant positive correlations with clinical parameters and levels of IL-17A 
and IL-17F. In contrast, GCF BChE activity is significantly decreased in patients with 
gingivitis and periodontitis and showed significant negative correlations with clinical 
parameters and levels of IL-17A and IL-17F. 
 
A limitation of this study was the fact that smoking was not considered as an exclusion 
factor. Evidence suggests that smoking can impact on non-neuronal cholinergic mechanisms 
(Wessler and Kirkpatrick, 2008, Wessler et al., 2003, Beckmann and Lips, 2013). 
Furthermore, smoking has profound effects on the immune system (Qiu et al., 2017) and 
more specifically on IL-17 biology. Cigarette smoke extract and nicotine have been shown to 
downregulate Th17 responses (Peruzzo et al., 2016). Furthermore, IL-17 levels in GCF of 
gingivitis and periodontitis patients have been shown to be decreased in smokers compared 
to non-smokers (Peruzzo et al., 2016, Buduneli et al., 2009). However, in this study, 
weighted analysis to correct for smoking had little effects on the statistical significance of the 
perturbations in ACh levels and cholinesterase activity in biological fluids reported in 
periodontal diseases. Furthermore, key correlations between ACh levels, cholinesterase 
activity, clinical parameters and levels of inflammatory mediators remained significant when 
only never smokers were considered. Therefore, the evidence suggests that smoking status 
had little impact on the major findings reported.  
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The role of ACh as an anti-inflammatory neuroendocrine mediator has received a great deal 
of attention since the discovery of the cholinergic anti-inflammatory pathway (Borovikova et 
al., 2000). It is now well established that non-neuronal ACh, acting via the α7nAChR, can 
also negatively regulate proinflammatory mediator expression by both professional and non-
professional immune cells (Yoshikawa et al., 2006, de Jonge et al., 2005, Macpherson et al., 
2014). However, evidence from in vivo and in vitro infection models suggests that it is too 
simplistic to state that within complex mucosal tissues ACh acts purely in an anti-
inflammatory capacity (Giebelen et al., 2008, Giebelen et al., 2009, Rajendran et al., 2015). 
There is indeed evidence to support a role for ACh in promoting neutrophil recruitment, 
activation and neutrophil extracellular trap (NET) formation (Ruhnau et al., 2014, Xu et al., 
2008, Rajendran et al., 2015, Giebelen et al., 2008, Carmona-Rivera et al., 2017). A 
plausible explanation for these differential findings is the fact that immune cells possess a 
plethora of nicotinic and muscarinic receptors which may differentially regulate immune 
responses. For example muscarinic receptors, in particular the M3 subtype, have been 
found to promote innate immune responses both in vitro (Kawashima and Fujii, 2004, 
Buhling et al., 2007) and in vivo (McLean et al., 2016, Kistemaker et al., 2013). 
 
It is now evident that numerous immune cells express ChAT including T cells, B cells, 
dendritic cells and macrophages (Fujii et al., 2017). Evidence suggests that T and B cells 
can acquire the ability to produce ACh in the mucosa associated lymphoid tissue (MALT) 
prior to emigration to peripheral sites (Reardon et al., 2013). Interestingly, ChAT expression 
by B and T cells is hypothesised to be dependent on the establishment of the host 
microbiota and occurs in response to Toll-Like Receptor (TLR) agonists (Friswell et al., 
2010, Reardon et al., 2013). Furthermore, evidence suggests that the ability of immune cells 
to express ChAT is in fact transient and not lineage specific (Reardon et al., 2013). Immune 
cells, like neurons, have been shown to synthesise and store ACh. In T and B cells the 
actual release of ACh has been found to be regulated by Norepinephrine and 
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Cholecystokinin, respectively (Rosas-Ballina et al., 2011, Reardon et al., 2013). 
Furthermore, ChAT+ T cells and ChAT+ B cells have been shown to have differential 
immunomodulatory functions (Reardon et al., 2013). Moreover, there is now evidence for 
ChAT+ T cells with characteristics of both Treg (Reardon et al., 2013) and Th17 cells 
(Dhawan et al., 2016). Interestingly, ChAT+ Th17 cells have been identified in payer’s 
patches and the lamina propria of intestinal tissue and are activated by dendritic cells, in 
response to stimulation by adrenergic neurotransmitters, to release ACh, IL-17A, IL-22 and 
IFNγ which in turn drives antimicrobial peptide expression by the intestinal epithelia and 
results in alterations in the diversity and richness of the gut microflora (Dhawan et al., 2016). 
Therefore ACh may not only regulate the host response to complex multispecies biofilms but 
also influence biofilm composition directly therefore having much more complex roles in 
biofilm driven inflammatory diseases such as periodontal diseases.  
 
Extracellular ACh is extremely labile due to the action of esterases (Wessler et al. 2003). 
The amount of available ACh within tissues is therefore modulated by a careful balance of 
synthesis and degradation. In humans the principle cholinesterases are AChE and BChE 
(Wessler and Kirkpatrick, 2008).  Although AChE is thought to be principally membrane 
bound there is evidence that within some tissues, including the neuromuscular junction and 
brain, a soluble form exists (Hicks et al., 2011). In contrast, the presence of both membrane 
bound and soluble forms of BChE in humans is well documented (Darvesh et al., 2003). 
Evidence has shown that perturbations in BChE activity are associated with diseases with an 
inflammatory component (Darvesh et al., 2003). For example, serum BChE activity levels 
are reduced in sterile inflammatory responses to surgery and in response to traumatic injury 
(Zivkovic et al., 2017, Zivkovic et al., 2016). Moreover, genetic variations in BChE have been 
associated with autoimmune diseases such as arthritis and multiple sclerosis 
(Shahmohamadnejad et al., 2015, Reale et al., 2018). 
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Based on current findings, and previous data, there is strong evidence for a role of 
dysregulated cholinergic mechanisms in the pathogenesis of periodontal disease. The strong 
correlations between elevated levels of ACh and proinflammatory members of the IL-17 
family of cytokines at specific sites open up the possibility that ChAT+ Th17 cells may play a 
role in modulating the oral microbiota, as observed in the intestinal mucosa (Dhawan et al., 
2016), and thus contribute to the aetiopathogeneis of periodontal disease. Furthermore, the 
elevated levels of ACh in GCF at inflamed sites may in part due to decreased BChE activity 
which in turn may be due to polymorphisms in the BChE gene. However, further in vitro and 
in vivo studies are required to unravel the mechanistics behind these clinical findings. That 
said, the data described herein open up the potential that therapeutic modalities targeting 
cholinergic mechanisms may be of use for the treatment of periodontal diseases. 
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Figure Legends 
Figure 1: Saliva and gingival crevicular fluid levels of acetylcholine are upregulated in 
periodontal diseases. Comparison of saliva (A) and gingival crevicular fluid (B) levels 
of ACh between healthy subjects, subjects diagnosed with gingivitis and subjects diagnosed 
with periodontitis.  The statistical significances shown are following adjustment for age and 
smoking. *p<0.05, **p<0.01,***p<0.01.  
 
Figure 2: Gingival crevicular fluid butyrylcholinesterase activity is decreased in 
periodontal diseases. Comparison of saliva (A) and gingival crevicular fluid (B) levels 
of AChE activity between healthy subjects, subjects diagnosed with gingivitis and subjects 
diagnosed with periodontitis.  Comparison of saliva (C) and gingival crevicular fluid (D) levels 
of BChE activity between healthy subjects, subjects diagnosed with gingivitis and subjects 
diagnosed with periodontitis. The statistical significances shown are following adjustment for 
age and smoking. *p<0.05, **p<0.01,***p<0.01.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1 
         Healthy (n=50)        Gingivitis (n=52)             Periodontitis (n=49) 
Female 68 % (n=34) 46 %  (n=24) 47 % (n=23) 
Smokers 18 % (n=9) 22 %  (n=12)* 49 %  (n=24)* 
Former smokers  
Never smokers 
0 % (n=0) 
82 % (n=41) 
10 %   (n=5) 
68 %  (n=35) 
14 %  (n=7) 
37 %  (n=18) 
    Mean             (95% CI)   Mean             (95% CI)   Mean                (95% CI) 
Cigs/days*yrs 13335 (-16975 – 43646) 20729 (-8982 - 50439) 115824  (85514 - 146135)*** ††† 
AGE 32.5 (28.9 - 36.1) 35.5 (32.0 -39.0) 50.2 (46.7 - 53.8)***††† 
BOP 0.13 (0.09  ‒ 0.17) 0.37    (0.31  ‒ 0.44)*** 0.53 (0.38  ‒ 0.68)***††† 
PI 0.24 (0.19  ‒ 0.30) 0.58    (0.49  ‒ 0.68)*** 0.59       (0.38  ‒ 0.84)*** 
PPD 1.79 (1.47  ‒ 1.60) 1.80 (1.70  ‒ 2.00) 2.96 (2.74  ‒ 3.20)***††† 
CAL 1.59 (1.50  ‒ 1.70) 1.80 (1.60  ‒ 2.00) 3.60 (3.26  ‒ 3.95)***††† 
PPD ≥ 5 mm 0.15 (-0 64 ‒ 0.95) 1.00 (-0.33  ‒ 2.34) 11.9 (0.93  ‒ 13.75)***††† 
PPD > 7 mm 0.00 (-0.20  ‒ 0.20) 0.19 (-0.15  ‒ 0.52) 2.13 (0.16  ‒ 2.60)***††† 
PPD 5-7 mm 0.15 (-0.49  ‒ 0.79) 0.81 (-0.27  ‒ 1.90) 9.71 (8.17  ‒ 11.24)***††† 
mean PPD ≥ 5 mm 0.00 (-0.01 ‒ 0.01) 0.01 (-0 .01‒ 0.02) 0.09 0.07  ‒ 0.10)***††† 
mean PPD > 7 mm 0.00 (0.00  ‒ 0.00) 0.00 (0 00 ‒ 0.00) 0.02 (0.01  ‒ 0.05)***††† 
mean PPD 5-7 mm 0.00 (-0.01  ‒ 0.01) 0.01 (-0.01  ‒ 0.02) 0.07 (1.79  ‒ 2.20)***††† 
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sBOP 0.11 (0.05  ‒ 0.17) 0.47      (0.37  ‒ 0.58)*** 0.72 (0.06  ‒ 0.08)***††† 
sPI 0.18 (0.12  ‒ 0.25) 0.51      (0.50  ‒ 0.72)*** 0.51      (0.34  ‒ 0.68)*** 
sPPD 1.54 (1.40  ‒ 1.68) 1.86  (1.68  ‒ 2.14) 5.14 (4.80  ‒ 5.48)***††† 
sCAL 1.7 (1.4  ‒ 1.8) 1.87  (1.54  ‒ 2.21) 5.64 (5.30  ‒ 5.99)***††† 
 
*Significantly different from the healthy group, † significantly different between the periodontitis and gingivitis group. BOP = full 
mouth bleeding on probing, PI = full mouth plaque index, PPD = full mouth pocket depth, CAL = full mouth attachment loss, PPD ≥ 
5 mm = number of sites in mouth with a PD equal to or greater than 5 mm, PPD ≥ 7 mm = number of sites in mouth with a PD 
equal to or greater than 7 mm, PPD 5-7 mm = number of sites in mouth with a PD between 5 and 7 mm. s= clinical parameters at 
specific GCF sampling site. Data in italics is not weighted. The statistical analysis of the clinical indices was weighted to correct for 
age and smoking.  
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Table 2        
         Healthy (n=50)       Gingivitis (n=52)       Periodontitis (n=49) 
  
Mean        (95% CI)    Mean        (95% CI)       Mean        (95% CI) 
A. Saliva    
IL-17A 229.7    (111.0-348.4)   78.4    (-131.2-288.0)   924.3    (591.0-1257.6)***†† 
IL-17F 152.2    (48.7-255.7) 104.2    (-78.4-286.9)   170.2    (-120.3-460.7) 
IL-17A/F 157.3    (82.5-232.1)   86.0    (-46.1-218.0)   520.7    (310.7-730.6) ***††† 
IL-17E 198.4    (133.9-262.9) 142.1    (28.3-255.9)   111.2    (-69.8-292.2) 
IL-17A/IL-17E 0.337    (0.135-0.539) 0.169    (-0.188-0.526)      2.31    (1.71-2.82) ***††† 
IL-4 
 
129.6    (87.3-172.0) 127.2    (52.5-202)   151.8     (33.0-270.7)* 
IL-6 
 
369.2    (111.7-626.7) 875.7    (421.1-1330.3) 1252.9    (529.9-1975.9) 
TNF 
 
540.0    (336.1-743.9)   78.7    (-281.2-438.7)   499.5    (-73.0-1071.9) 
TGF-β 
 
235.9    (174.1-297.7) 244.5    (135.4-353.6)   112.3    (-61.2-285.9) 
IL-23 
 
112.7    (36.9-188.6)   80.7    (-53.173-214.5)   134.3    (-78.6-347.1) 
IL-23R   48.2    (33.5-62.9)   47.8    (21.9-73.8)     39.5    (-1.8-80.8) 
B. GCF    
IL-17A   20.5    (9.5-31.5)   51.1    (31.7-70.5)*   114.7    (83.8-145.6)**† 
IL-17F   15.8    (8.2-23.4)   47.4    (34.0-60.8)*   133.4    (112.1-154.7)**† 
IL-17A/F     9.5    (-1.9-20.9)   60.1    (40.0-80.2)*     25.6    (-6.3-57.6)† 
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IL-17E   24.4    (17.3-31.4)   15.6    (3.1-28.0)     18.2    (-1.6-37.9) 
IL-17A/IL-17E     1.1    (-1.2-3.4)   10.0    (6.0-14.1)**       9.1    (3.6-14.5)* 
IL-4 
 
    2.7     (2.2-3.2)     3.8    (2.9-4.7)       5.3    (3.9-6.8)* 
IL-6 
 
    7.8    (4.6-11.0)   12.9    (7.3-18.6)     30.0    (20.9-39.0)*† 
TNF 
 
  17.3    (14.0-20.5)   16.0    (10.2-21.7)     19.3    (10.1-28.4) 
TGF-β 
 
  32.2    (30.0-34.5)   23.0    (19.0-27.0)     20.5    (14.2-26.9)* 
IL-23 
 
    6.5    (3.0-10.1)     6.2    (-0.1-12.5)       5.5   (-4.5-15.4) 
IL-23R   13.0    (6.7-19.2)   26.6    (15.5-37.7)       9.8    (-7.9-27.4) 
*Significantly different from the healthy group, † significant difference between periodontitis and gingivitis group. 
The statistical analysis was weighted to correct for age and smoking. 
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Table 3 
A. Saliva 
    
        AChE  
     AP      NS 
       BChE  
    AP       NS 
        BOP 
    AP       NS 
          PI 
    AP       NS 
        PPD 
   AP      NS 
        CAL 
   AP      NS 
    mean PPD 
≥5mm 
       AP      NS 
ACh  r -.072   -.020 .015     .030 .165*       .235* .196*      .236* .289***   .263** .295***   .271** .273***   .203** 
(nmol/ml) p  .387    .844 .853     .773 .043      .022 .016     .022 <.001    .009 <.001   .008 .001     .049 
  n 151       94 151         94 151         94 151        94 151       94 151      94 151        94 
AChE  r 
 
.481***    .540*** .173*        .179 .216**     .204* .158     .222** .137     .187 .207*       .350*** 
(Units) p 
 
<.001  <.001 .036      .085 .008      .049 .055      .032 .096     .073 .012      .001 
  n 
 
151         94 151         94 151        94 151       94 151       94 151         94 
BChE r 
  
.152      .165 .118     .088 .120      .122 .095     .092 .168*      .162 
(Units) p 
  
.065      .112 .152     .400 .146      .245 .253     .873 .041      .121 
  n 
  
151        94 151       94 151        94 151       94 151         94 
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B. GCF 
    
AChE 
    All        NS  
BChE   
 All        NS 
sBOP 
All        NS 
sPI 
All        NS 
sPPD 
All        NS 
 sCAL 
    All       NS 
ACh  r .151    .122 -.215**  -.184 .407***    .459*** .306***  .322*** .545***  .560*** .560***   .560*** 
(nmol/ml) p  .064    .239 .008     .082 <.001  <.001 <.001   .001 <.001  <.001 <.001  <.001 
  n 151        94 151        94 151       94 151     94 151      94 151      94 
AChE  r 
 
.270***    .286** .256**       .201 .208*     .222* .139    .120 .149     .116 
(Units) p 
 
.001      .005 .002      .055 .011      .031 .090    .246 .069     .249 
  n 
 
151        94 151          94 151        94 151      94 151       94 
BChE r 
  
-.272***   -.278** -.144   -.048 -.256**  -.228* -.257**  -.219* 
(Units) p 
  
.001        .006 .079    .641 .002     .027 .002     .033 
  n 
  
151          94 151      94 151       94 151       94 
*Correlation is significant at the 0.05 level, ** at the 0.01 level, *** at the 0.001 level (all 2-tailed and shown in bold text). ACh = 
Acetylcholine, AChE = Acetylcholinesterase, BChE = Butyrlcholinesterase, AP = All participants, NS = Never smokers only.  
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Table 4 
A. Saliva 
    
IL-17A  
AP         NS 
 IL-17F  
 AP       NS 
IL-17A/F  
AP        NS 
IL-17A:IL-17E 
AP        NS 
IL-4 
AP       NS 
IL-6  
AP       NS 
TNF 
AP       NS 
ACh  r .201*   .082 -.017   .176 .224**   .107 -.057   .063 .000   .105 .018      .045 -.048    .191 
(nmol/ml) p  .014    .433 .838    .088 .006    .301 .497    .544 .996   .312 .828      .663 .588    .064 
  n 151        94 151        94 151       94 151       94 151       94 151         94 151      94 
AChE  r .064    .084 -.055  -.045 .058    .115 .003   -.049 -.074   .007 -.072    -.068 -.082   -.019 
(Units) p .442    .424 .505    .665 .487    .271 .972    .640 .370    .951 .384      .518 .322    .862 
  n 151        94 151        94 151       94 151      94 151      94 151        94 151      94 
BChE  r -.052    -.167 -.002   -.064 -.038   -.041 -.043  -.089 -.150  -.267** -.078    -.065 -.225* -.237* 
(Units) p .530     .110 .984     .554 .644     .690 .617   .396 .069   .008 .349     .537 .006    .022 
  n 151       94 151       94 151       94 151      94 151      94 151       94 151       94 
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B. GCF 
    
IL-17A  
   AP       NS 
IL-17F 
 AP      NS 
IL-17A/F 
 AP       NS 
IL-17A:IL-17E 
AP       NS 
IL-4  
AP     NS 
IL-6 
 AP      NS 
IL-23 
AP       NS 
ACh  r   .475***  .341*** .325***  .339*** -.024   .049 .212**     .149 .085   .093 .218**   .191 .154    .283* 
(nmol/ml) p  <.001  <.001 <.001 <.001 .774    .663 .009     .149 .300   .374 .007    .064 .059    .003 
  n 151       94 151      94 151       94 151        94 151      94 151       94 151        94 
AChE  r .044   -.023 .097   -.064 -.007  .038 .015    -.011 .164*   .246* -.005   -.024 .169*     .154 
(Units) p  .594    .842 .235    .535 .931   .712 .859     .912 .044   .016 .954    .817 .038     .137 
  n 151       94 151        94 151      94 151        94 151      94 151       94 151         94 
BChE  r -.213** -.308** -.247** -.221* -.086 -.271** -.170*    -.180 -.032  .004 -.218**   -.197 .079     .042 
(Units) p  .009    .008 .002    .032 .296    .032 .038     .080 .695  .960 .007    .056 .337     .668 
  n 151        94 151       94 151      94 151       94 151     94 151        94 151        94 
*Correlation is significant at the 0.05 level, ** at the 0.01 level, *** at the 0.001 level (all 2-tailed and shown in bold text). ACh = 
Acetylcholine, AChE = Acetylcholinesterase, BChE = Butyrlcholinesterase, AP = All participants, NS = Never smokers only.  
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